CLINICAL TRIALS PROFILE FOR PENICILLIN G BENZATHINE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for PENICILLIN G BENZATHINE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT05069974 ↗ | Alternative Antibiotics for Syphilis | Recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 3 | 2021-10-01 | The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for PENICILLIN G BENZATHINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00031499 ↗ | Azithromycin/Bicillin Syphilis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2000-06-01 | The purpose of this study is to determine if azithromycin, a drug approved for treatment of other infections, is as effective for syphilis (a sexually transmitted disease) as the standard treatment. Approximately 600 healthy adults, who are HIV-negative, ages 18 to 55 years of age, with primary, secondary or early latent syphilis, will participate in this research study. Volunteers will be enrolled in 5 U.S. cities and in Madagascar. Participants will be chosen randomly (by chance) to receive 1 of 2 study drugs: benzathine penicillin given (2 shots in the buttocks) or 4 tablets of azithromycin. Subjects who report a history of a penicillin allergy will be given either 2.0 g of oral azithromycin or 100 mg doxycycline taken orally, twice a day for 14 days. Over 2 years, 10 visits will be required. Procedures will include blood samples, physical exams, and swabs of sores. |
| NCT01156740 ↗ | Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings | Completed | Cairo University | N/A | 2001-08-01 | The purpose of this study was to compare the microbiological effects of two different treatments: a single dose of intramuscular benzathine penicillin G (IM BPG) vs. a 10-day daily dose of amoxicillin for the treatment of GABHS pharyngitis in children in low resource settings. This study was a prospective multi-center randomized active control treatment trial. The trial is a non-inferiority equivalence trial, to determine if amoxicillin treatment is at least as effective as the currently given IM BPG treatment. |
| NCT01156740 ↗ | Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings | Completed | United States Agency for International Development (USAID) | N/A | 2001-08-01 | The purpose of this study was to compare the microbiological effects of two different treatments: a single dose of intramuscular benzathine penicillin G (IM BPG) vs. a 10-day daily dose of amoxicillin for the treatment of GABHS pharyngitis in children in low resource settings. This study was a prospective multi-center randomized active control treatment trial. The trial is a non-inferiority equivalence trial, to determine if amoxicillin treatment is at least as effective as the currently given IM BPG treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PENICILLIN G BENZATHINE
Condition Name
Clinical Trial Locations for PENICILLIN G BENZATHINE
Trials by Country
Clinical Trial Progress for PENICILLIN G BENZATHINE
Clinical Trial Phase
Clinical Trial Sponsors for PENICILLIN G BENZATHINE
Sponsor Name
